{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:12:15Z","timestamp":1778803935871,"version":"3.51.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["P30CA196521"],"award-info":[{"award-number":["P30CA196521"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.canep.2021.101974","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T17:55:22Z","timestamp":1625594122000},"page":"101974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Multiple myeloma, race, insurance and treatment"],"prefix":"10.1016","volume":"73","author":[{"given":"Himanshu","family":"Joshi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kezhen","family":"Fei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne S.","family":"Renteria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhu","family":"Mazumdar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sundar","family":"Jagannath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina A.","family":"Bickell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canep.2021.101974_bib0005","year":"2019"},{"key":"10.1016\/j.canep.2021.101974_bib0010","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma \u2014 an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canep.2021.101974_bib0015","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med."},{"key":"10.1016\/j.canep.2021.101974_bib0020","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2012.09124.x","article-title":"Outcome disparities in multiple myeloma: a SEER-based comparative analysis of ethnic subgroups","author":"Ailawadhi","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2021.101974_bib0025","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials [Internet]","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.canep.2021.101974_bib0030","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","author":"Schriber","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2021.101974_bib0035","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study [Internet]","volume":"121","author":"Bhatnagar","year":"2015","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.canep.2021.101974_bib0040","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canep.2021.101974_bib0045","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1200\/JCO.2017.72.2447","article-title":"Subsidies for oral chemotherapy and use of immunomodulatory drugs among medicare beneficiaries with myeloma","volume":"35","author":"Olszewski","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"43\u201350","key":"10.1016\/j.canep.2021.101974_bib0050","first-page":"e4","article-title":"Where you live can impact your cancer risk: a look at multiple myeloma in New York City","volume":"48","author":"Kamath","year":"2020","journal-title":"Ann. Epidemiol."},{"key":"10.1016\/j.canep.2021.101974_bib0055","series-title":"American College of Surgeons: Optimal Resources for Cancer Care:2020 Standards","year":"2020"},{"key":"10.1016\/j.canep.2021.101974_bib0060","series-title":"NCCN Clinical Practice Guidelines in Oncology. Multiple Myeloma (Version 2.2014).","author":"National Comprehensive Cancer Network","year":"2014"},{"issue":"3","key":"10.1016\/j.canep.2021.101974_bib0065","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.bbmt.2013.12.557","article-title":"Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma","volume":"20","author":"AymanSaad","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"10","key":"10.1016\/j.canep.2021.101974_bib0070","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.bbmt.2017.06.001","article-title":"Evaluation of performance status and hematopoietic cell transplantation specific comorbidity index on unplanned admission rates in patients with multiple myeloma undergoing outpatient autologous stem cell transplantation","volume":"23","author":"Obiozor","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.canep.2021.101974_bib0075","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.maturitas.2014.11.017","article-title":"Managing multiple myeloma in the over 70s: a review","volume":"80","author":"King","year":"2015","journal-title":"Maturitas"},{"key":"10.1016\/j.canep.2021.101974_bib0080","series-title":"Race and Multiracial Americans in the U.S. Census","author":"Parker","year":"2015"},{"key":"10.1016\/j.canep.2021.101974_bib0085","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/leu.2011.368","article-title":"Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites","volume":"26","author":"Greenberg","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.canep.2021.101974_bib0090","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.101974_bib0095","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2013-03-487215","article-title":"Multiethnic myeloma","volume":"121","author":"Weiss","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.101974_bib0100","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study [Internet]","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.101974_bib0105","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.bbmt.2019.12.116","article-title":"Stem cell transplant minimizes insurance coverage-driven outcome disparities for multiple myeloma patients","volume":"26","author":"Schmikla","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.canep.2021.101974_bib0110","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.bbmt.2016.03.008","article-title":"Time to insurance approval in private and public payers does not influence survival in patients who undergo hematopoietic cell transplantation","volume":"22","author":"Bhatt","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.canep.2021.101974_bib0115","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/j.bbmt.2007.09.006","article-title":"Disparity in survival outcome after hematopoietic stem cell transplantation for hematologic malignancies according to area of primary residence","volume":"13","author":"Rao","year":"2007","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.canep.2021.101974_bib0120","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","article-title":"Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study","volume":"2","author":"Huntington","year":"2015","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.canep.2021.101974_bib0125","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1200\/JCO.19.01564","article-title":"Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation","volume":"38","author":"Yabroff","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0130","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/cam4.2058","article-title":"Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: clinical benefit and price considerations","volume":"8","author":"Jiang","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.canep.2021.101974_bib0135","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1093\/annonc\/mdw540","article-title":"Cancer-related financial toxicity: beyond the realm of drug pricing and out-of-pocket costs","volume":"27","author":"Huntington","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0140","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jamaoncol.2017.2148","article-title":"Out-of-pocket costs, financial distress, and underinsurance in cancer care. [Internet]","volume":"3","author":"Chino","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0145","series-title":"Phone Survey Response Rates Decline Again | [Internet]","author":"Kennedy","year":"2019"},{"key":"10.1016\/j.canep.2021.101974_bib0150","article-title":"Induction therapy in multiple myeloma. [Internet]","volume":"306\u2013312","author":"Harousseau","year":"2008","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.canep.2021.101974_bib0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.8033","article-title":"Multimorbidity patterns and their association with survival in a large national cohort of older veterans with multiple myeloma","volume":"37","author":"Fillmore","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0160","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.760.760","article-title":"Comorbidities impact survival in multiple myeloma: analysis of the veterans health administration national database","volume":"120","author":"Wildes","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.101974_bib0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0170","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.18_suppl.LBA107","article-title":"Insurance status and survival of multiple myeloma (MM) patients","volume":"37","author":"Chamoun","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0175","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma [Internet]","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2021.101974_bib0180","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canep.2021.101974_bib0185","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djy073","article-title":"Association between autologous stem cell transplant and survival among californians with multiple myeloma","author":"Rosenberg","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canep.2021.101974_bib0190","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canep.2021.101974_bib0195","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2012.32.21","article-title":"Maintenance therapy for myeloma: how much, how long, and at what cost?","author":"Attal","year":"2012","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"August 6","key":"10.1016\/j.canep.2021.101974_bib0200","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1182\/blood-2014-03-544759","article-title":"How we manage autologous stem cell transplantation for patients with multiple myeloma","volume":"124","author":"Gertz","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.canep.2021.101974_bib0205","unstructured":"Center of Medicare and Medicaid Services. Decision Memo for Autologous Stem Cell Transplantation (AuSCT) for Multiple Myeloma (CAG-00011N). 2000. Available at: https:\/\/www.cms.gov\/medicare-coverage-database\/details\/nca-decision-memo.aspx?NCAId=10&bc=ACAAAAAAQAAA&."},{"key":"10.1016\/j.canep.2021.101974_bib0210","unstructured":"Bluecross Blueshied. Medicare Part C Medical Coverage Policy for Stem Cell transplant. 2016. Available at: https:\/\/www.bluecrossnc.com\/sites\/default\/files\/document\/attachment\/services\/public\/pdfs\/bluemedicare\/medicalpolicy\/transplant_stem_cell.pdf."}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121000916?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782121000916?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T05:28:07Z","timestamp":1761802087000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782121000916"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":42,"alternative-id":["S1877782121000916"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2021.101974","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma, race, insurance and treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2021.101974","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101974"}}